Which has higher earnings & valuation, OGN or PHAR?

Organon & Co. has higher revenue and earnings than Pharming Group. Organon & Co. is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.22B 0.57 $187M $0.93 14.47 Pharming Group $369.49M 2.47 $2.85M $0.16 80.69

Which has preferable valuation and earnings, PHAR or TLX?

Pharming Group has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharming Group $369.49M 2.47 $2.85M $0.16 80.69 Telix Pharmaceuticals $803.79M 4.13 -$7.12M N/A N/A

Pharming Group (PHAR) Competitors

$12.91 +0.10 (+0.79%)

As of 10:04 AM Eastern

Compare

PHAR vs. OGN, VKTX, TLX, DNLI, and BEAM

Should you buy Pharming Group stock or one of its competitors? MarketBeat compares Pharming Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharming Group include Organon & Co. (OGN), Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Pharming Group compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Organon & Co. currently has a consensus price target of $11.40, suggesting a potential downside of 15.27%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 196.90%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Organon & Co. had 7 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Organon & Co. and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.87 beat Organon & Co.'s score of 1.11 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Organon & Co.	Positive
Pharming Group	Very Positive

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Pharming Group. Organon & Co. is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.47
Pharming Group	$369.49M	2.47	$2.85M	$0.16	80.69

Organon & Co. has a net margin of 3.99% compared to Pharming Group's net margin of 3.30%. Organon & Co.'s return on equity of 99.95% beat Pharming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Pharming Group	3.30%	4.64%	2.55%

Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

Summary

Organon & Co. beats Pharming Group on 9 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Viking Therapeutics?

Pharming Group (NASDAQ:PHAR) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Pharming Group has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.47	$2.85M	$0.16	80.69
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Viking Therapeutics had 6 more articles in the media than Pharming Group. MarketBeat recorded 7 mentions for Viking Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.87 beat Viking Therapeutics' score of 0.40 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Very Positive
Viking Therapeutics	Neutral

Pharming Group has a net margin of 3.30% compared to Viking Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Viking Therapeutics	N/A	-71.31%	-65.35%

Pharming Group currently has a consensus price target of $38.33, indicating a potential upside of 196.90%. Viking Therapeutics has a consensus price target of $93.60, indicating a potential upside of 218.31%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

Pharming Group and Viking Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Telix Pharmaceuticals?

Pharming Group (NASDAQ:PHAR) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Pharming Group has a net margin of 3.30% compared to Telix Pharmaceuticals' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Telix Pharmaceuticals	N/A	N/A	N/A

Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

Pharming Group has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.47	$2.85M	$0.16	80.69
Telix Pharmaceuticals	$803.79M	4.13	-$7.12M	N/A	N/A

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Pharming Group. MarketBeat recorded 2 mentions for Telix Pharmaceuticals and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.87 beat Telix Pharmaceuticals' score of 1.50 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Very Positive
Telix Pharmaceuticals	Very Positive

0.0% of Pharming Group shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pharming Group currently has a consensus price target of $38.33, suggesting a potential upside of 196.90%. Telix Pharmaceuticals has a consensus price target of $21.13, suggesting a potential upside of 116.22%. Given Pharming Group's higher probable upside, analysts clearly believe Pharming Group is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Pharming Group beats Telix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Pharming Group compare to Denali Therapeutics?

Pharming Group (NASDAQ:PHAR) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Pharming Group and Pharming Group both had 1 articles in the media. Pharming Group's average media sentiment score of 1.87 equaled Denali Therapeutics'average media sentiment score.

Company	Overall Sentiment
Pharming Group	Very Positive
Denali Therapeutics	Very Positive

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.47	$2.85M	$0.16	80.69
Denali Therapeutics	$330.53M	10.56	-$512.54M	-$2.88	N/A

Pharming Group has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Pharming Group currently has a consensus price target of $38.33, suggesting a potential upside of 196.90%. Denali Therapeutics has a consensus price target of $34.25, suggesting a potential upside of 55.77%. Given Pharming Group's higher probable upside, equities research analysts plainly believe Pharming Group is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Pharming Group has a net margin of 3.30% compared to Denali Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Pharming Group beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Pharming Group compare to Beam Therapeutics?

Pharming Group (NASDAQ:PHAR) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.47	$2.85M	$0.16	80.69
Beam Therapeutics	$139.74M	22.37	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 3 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Beam Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.87 beat Beam Therapeutics' score of 1.30 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Very Positive
Beam Therapeutics	Positive

Pharming Group has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Pharming Group presently has a consensus price target of $38.33, suggesting a potential upside of 196.90%. Beam Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 54.12%. Given Pharming Group's higher possible upside, research analysts plainly believe Pharming Group is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Pharming Group has a net margin of 3.30% compared to Beam Therapeutics' net margin of -39.66%. Pharming Group's return on equity of 4.64% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Pharming Group beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$913.96M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	80.89	20.05	24.05	24.76
Price / Sales	2.47	325.48	542.61	168.32
Price / Cash	63.85	53.61	27.48	37.92
Price / Book	3.27	8.16	10.69	6.90
Net Income	$2.85M	$23.89M	$3.57B	$337.45M
7 Day Performance	0.87%	3.66%	1.56%	2.84%
1 Month Performance	-0.07%	1.69%	2.49%	4.78%
1 Year Performance	18.77%	46.95%	26.51%	33.08%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	4.023 of 5 stars	$12.91 +0.8%	$38.33 +196.9%	+17.8%	$913.96M	$369.49M	80.89	280	Positive News Gap Up
OGN Organon & Co.	3.1516 of 5 stars	$13.41 +0.1%	$11.40 -15.0%	+34.2%	$3.52B	$6.22B	14.42	10,000	Positive News
VKTX Viking Therapeutics	2.4736 of 5 stars	$29.26 +0.1%	$93.60 +219.9%	+10.2%	$3.40B	N/A	N/A	20
TLX Telix Pharmaceuticals	4.4991 of 5 stars	$9.43 +2.2%	$21.13 +124.1%	-40.6%	$3.20B	$803.79M	N/A	1,184
DNLI Denali Therapeutics	3.2317 of 5 stars	$20.06 +2.7%	$34.25 +70.7%	+48.9%	$3.18B	$330.53M	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. OGN, VKTX, TLX, DNLI, and BEAM

How does Pharming Group compare to Organon & Co.?

Summary

How does Pharming Group compare to Viking Therapeutics?

Summary

How does Pharming Group compare to Telix Pharmaceuticals?

Summary

How does Pharming Group compare to Denali Therapeutics?

Summary

How does Pharming Group compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. OGN, VKTX, TLX, DNLI, and BEAM

How does Pharming Group compare to Organon & Co.?

Do analysts recommend OGN or PHAR?

Does the media favor OGN or PHAR?

Do institutionals and insiders hold more shares of OGN or PHAR?

Which has higher earnings & valuation, OGN or PHAR?

Is OGN or PHAR more profitable?

Which has more risk and volatility, OGN or PHAR?

Summary

How does Pharming Group compare to Viking Therapeutics?

Which has preferable earnings and valuation, PHAR or VKTX?

Do insiders & institutionals have more ownership in PHAR or VKTX?

Does the media refer more to PHAR or VKTX?

Is PHAR or VKTX more profitable?

Do analysts recommend PHAR or VKTX?

Which has more risk and volatility, PHAR or VKTX?

Summary

How does Pharming Group compare to Telix Pharmaceuticals?

Is PHAR or TLX more profitable?

Which has more risk & volatility, PHAR or TLX?

Which has preferable valuation and earnings, PHAR or TLX?

Does the media favor PHAR or TLX?

Do institutionals and insiders hold more shares of PHAR or TLX?

Do analysts recommend PHAR or TLX?

Summary

How does Pharming Group compare to Denali Therapeutics?

Does the media favor PHAR or DNLI?

Do insiders and institutionals have more ownership in PHAR or DNLI?

Which has better valuation & earnings, PHAR or DNLI?

Which has more risk and volatility, PHAR or DNLI?

Do analysts rate PHAR or DNLI?

Is PHAR or DNLI more profitable?

Summary

How does Pharming Group compare to Beam Therapeutics?

Do institutionals and insiders have more ownership in PHAR or BEAM?

Which has stronger valuation and earnings, PHAR or BEAM?

Does the media refer more to PHAR or BEAM?

Which has more volatility & risk, PHAR or BEAM?

Do analysts rate PHAR or BEAM?

Is PHAR or BEAM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools